-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ span.
Maiwei Bio has established a market-leading, medical-driven, access The first integrated professional academic promotion and marketing team, based in China and looking at the world
China's rheumatoid arthritis, ankylosing spondylitis and silver There are more than 15 million psoriasis patients.
Since its establishment in 2017, Maiwei Bio has built an innovative system starting from antibody drug target discovery and molecular discovery, covering the whole cycle of drug research and development, such as druggability research, preclinical research, clinical research, and production transformation, to achieve integrated research and development, production.
These statements are inherently subject to considerable risk and uncertainty
These statements are not guarantees for future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict
Dr.
Liu Datao, co-founder and CEO of Maiwei Bio, said: "This is the first drug that is marketed by Maiwei Bio, and it is also an important milestone for us to truly realize the layout of the entire industry chain
.
Maiwei Bio has established a market-leading, medical-driven, access The first integrated professional academic promotion and marketing team, based in China and looking at the world
Dr.
Li Ning, CEO of Junshi Bio, said: "On the tenth anniversary of Junshi Bio's establishment, we are delighted to see the company's third product successfully enter the commercialization stage
.
China's rheumatoid arthritis, ankylosing spondylitis and silver There are more than 15 million psoriasis patients.
About Maiwei Bio
Maiwei Bio (688062) is an innovative biopharmaceutical company with a whole industry chain layout.
It has always adhered to the vision of "turning innovation from dream into reality", and practiced the mission of "exploring life and benefiting health".
Provide patients with innovative biological drugs with better efficacy and greater accessibility to meet the unmet clinical needs of the world
.
Since its establishment in 2017, Maiwei Bio has built an innovative system starting from antibody drug target discovery and molecular discovery, covering the whole cycle of drug research and development, such as druggability research, preclinical research, clinical research, and production transformation, to achieve integrated research and development, production.
Forward-Looking Statements
Information published in this press release may contain certain forward-looking statements
.
These statements are inherently subject to considerable risk and uncertainty
These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made
.
These statements are not guarantees for future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict
The Company, its directors and employee agents disclaim (a) any obligation to correct or update the forward-looking statements contained in this website; and (b) any responsibility
